{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:12:37Z","timestamp":1790993557253,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04402-9","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:28:23Z","timestamp":1783942103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenomics in oncology: mutation-targeted therapy and biomarker integration in non-small cell lung cancer"],"prefix":"10.1007","author":[{"given":"Mohammad Noor","family":"Shaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutham","family":"Yerrakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabbathy Raghunathachar","family":"Sahana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi Aruna Jyothi","family":"Bommareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adepu","family":"Himavarshini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badvel Jeevan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi Swaroopa","family":"Borra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-4849","authenticated-orcid":false,"given":"Nagaraju","family":"Bandaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"4402_CR1","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.3390\/jcm13144189","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Singhal S, Kulkarni P, Horne D, Malhotra J, Salgia R, et al. Advances in non-small cell lung cancer: current insights and future directions. J Clin Med. 2024;13:4189. https:\/\/doi.org\/10.3390\/jcm13144189.","journal-title":"J Clin Med"},{"key":"4402_CR2","doi-asserted-by":"publisher","first-page":"100430","DOI":"10.1016\/j.lansea.2024.100430","volume":"27","author":"V Noronha","year":"2024","unstructured":"Noronha V, Budukh A, Chaturvedi P, Anne S, Punjabi A, Bhaskar M, et al. Uniqueness of lung cancer in Southeast Asia. Lancet Reg Health Southeast Asia. 2024;27:100430. https:\/\/doi.org\/10.1016\/j.lansea.2024.100430.","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"4402_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","volume":"136","author":"C Li","year":"2023","unstructured":"Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136:1583\u201390. https:\/\/doi.org\/10.1097\/CM9.0000000000002529.","journal-title":"Chin Med J (Engl)"},{"key":"4402_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94:1623\u201340. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013.","journal-title":"Mayo Clin Proc"},{"key":"4402_CR5","doi-asserted-by":"publisher","first-page":"e2355331","DOI":"10.1001\/jamanetworkopen.2023.55331","volume":"7","author":"HA Jung","year":"2024","unstructured":"Jung HA, Lee DH, Lim SM, Yu H, Yoon S, Kim D, et al. Epidemiology and outcomes of non-small cell lung cancer in South Korea. JAMA Netw Open. 2024;7:e2355331. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.55331.","journal-title":"JAMA Netw Open"},{"key":"4402_CR6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026. https:\/\/doi.org\/10.3322\/caac.70043.","journal-title":"CA Cancer J Clin"},{"key":"4402_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","volume":"10","author":"A Casal-Mouri\u00f1o","year":"2021","unstructured":"Casal-Mouri\u00f1o A, Ruano-Ravina A, Lorenzo-Gonz\u00e1lez M, Rodr\u00edguez-Mart\u00ednez \u00c1, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10:506\u201318. https:\/\/doi.org\/10.21037\/tlcr.2020.03.40.","journal-title":"Transl Lung Cancer Res"},{"key":"4402_CR8","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7:1824. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4932.","journal-title":"JAMA Oncol"},{"key":"4402_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"4402_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4103\/ijmr.ijmr_1364_21","volume":"155","author":"A Nath","year":"2022","unstructured":"Nath A, Sathishkumar K, Das P, Sudarshan KL, Mathur P. A clinicoepidemiological profile of lung cancers in India\u2014results from the National Cancer Registry Programme. Indian J Med Res. 2022;155:264\u201372. https:\/\/doi.org\/10.4103\/ijmr.ijmr_1364_21.","journal-title":"Indian J Med Res"},{"key":"4402_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.25259\/ijmr_118_24","volume":"160","author":"N Ramnath","year":"2025","unstructured":"Ramnath N, Ganesan P, Penumadu P, Arenberg D, Bryant A. Lung cancer screening in India: preparing for the future using smart tools & biomarkers to identify highest risk individuals. Indian J Med Res. 2025;160:561. https:\/\/doi.org\/10.25259\/ijmr_118_24.","journal-title":"Indian J Med Res"},{"key":"4402_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cllc.2013.04.001","volume":"14","author":"W Uyterlinde","year":"2013","unstructured":"Uyterlinde W, Belderbos J, Baas C, van Werkhoven E, Knegjens J, Baas P, et al. Prediction of acute toxicity grade \u2265 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose cisplatin. Clin Lung Cancer. 2013;14:541\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2013.04.001.","journal-title":"Clin Lung Cancer"},{"key":"4402_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cancers17050785","volume":"17","author":"P Uniyal","year":"2025","unstructured":"Uniyal P, Kashyap VK, Behl T, Parashar D, Rawat R. KRAS mutations in cancer: understanding signaling pathways to immune regulation and the potential of immunotherapy. Cancers (Basel). 2025;17:785. https:\/\/doi.org\/10.3390\/cancers17050785.","journal-title":"Cancers (Basel)"},{"key":"4402_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/cancers17030441","volume":"17","author":"WJ MacDonald","year":"2025","unstructured":"MacDonald WJ, Purcell C, Pinho-Schwermann M, Stubbs NM, Srinivasan PR, El-Deiry WS. Heterogeneity in cancer. Cancers (Basel). 2025;17:441. https:\/\/doi.org\/10.3390\/cancers17030441.","journal-title":"Cancers (Basel)"},{"key":"4402_CR15","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.amolm.2025.100073","volume":"5","author":"M Namini","year":"2025","unstructured":"Namini M, Bhagya G, Sharma M. Personalized approaches to lung cancer treatment: a review of targeted therapies, pharmacogenomics, and combination strategies. Aspects Mol Med. 2025;5:100073. https:\/\/doi.org\/10.1016\/j.amolm.2025.100073.","journal-title":"Aspects Mol Med"},{"key":"4402_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/clpt.2010.279","volume":"89","author":"MV Relling","year":"2011","unstructured":"Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89:464\u20137. https:\/\/doi.org\/10.1038\/clpt.2010.279.","journal-title":"Clin Pharmacol Ther"},{"key":"4402_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/clpt.2013.172","volume":"94","author":"KE Caudle","year":"2013","unstructured":"Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94:640\u20135. https:\/\/doi.org\/10.1038\/clpt.2013.172.","journal-title":"Clin Pharmacol Ther"},{"key":"4402_CR18","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2246.","journal-title":"Clin Cancer Res"},{"key":"4402_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/138161210790112719","volume":"16","author":"D Houtsma","year":"2010","unstructured":"Houtsma D, Guchelaar H, Gelderblom H. Pharmacogenetics in oncology: a promising field. Curr Pharm Des. 2010;16:155\u201363. https:\/\/doi.org\/10.2174\/138161210790112719.","journal-title":"Curr Pharm Des"},{"key":"4402_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000114642","volume":"3","author":"H Brauch","year":"2008","unstructured":"Brauch H, Schroth W, Eichelbaum M, Schwab M, Harbeck N. Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer. Breast Care Basel. 2008;3:43\u201350. https:\/\/doi.org\/10.1159\/000114642.","journal-title":"Breast Care Basel"},{"key":"4402_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337. https:\/\/doi.org\/10.1038\/s41416-019-0573-8.","journal-title":"Br J Cancer"},{"key":"4402_CR22","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland \u00c5, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(17)30679-4.","journal-title":"Lancet Oncol"},{"key":"4402_CR23","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","journal-title":"N Engl J Med"},{"key":"4402_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"key":"4402_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/FPC.0000000000000305","volume":"27","author":"AE Fohner","year":"2017","unstructured":"Fohner AE, Brackman DJ, Giacomini KM, Altman RB, Klein TE. PharmGKB summary. Pharmacogenet Genom. 2017;27:420\u20137. https:\/\/doi.org\/10.1097\/FPC.0000000000000305.","journal-title":"Pharmacogenet Genom"},{"key":"4402_CR26","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/biology10090864","volume":"10","author":"C Cainap","year":"2021","unstructured":"Cainap C, Balacescu O, Cainap SS, Pop L-A. Next-generation sequencing technology in lung cancer diagnosis. Biology. 2021;10:864. https:\/\/doi.org\/10.3390\/biology10090864.","journal-title":"Biology"},{"key":"4402_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12672-025-01816-9","volume":"16","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi N, Heidari R, Farhadi A, Chamanara M, Farahani N, Vahidi M, et al. Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discov Oncol. 2025;16:578. https:\/\/doi.org\/10.1007\/s12672-025-01816-9.","journal-title":"Discov Oncol"},{"key":"4402_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","author":"J Phallen","year":"2017","unstructured":"Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aan2415.","journal-title":"Sci Transl Med"},{"key":"4402_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12885-023-10674-z","volume":"23","author":"J Xie","year":"2023","unstructured":"Xie J, Yao W, Chen L, Zhu W, Liu Q, Geng G, et al. Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers. BMC Cancer. 2023;23:294. https:\/\/doi.org\/10.1186\/s12885-023-10674-z.","journal-title":"BMC Cancer"},{"key":"4402_CR30","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","volume":"83","author":"BJ Hindson","year":"2011","unstructured":"Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83:8604\u201310. https:\/\/doi.org\/10.1021\/ac202028g.","journal-title":"Anal Chem"},{"key":"4402_CR31","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1158\/1078-0432.CCR-17-1434","volume":"23","author":"M Nishino","year":"2017","unstructured":"Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, J\u00e4nne PA, et al. Tumor response dynamics of advanced non-small cell lung cancer patients treated with PD-1 inhibitors: imaging markers for treatment outcome. Clin Cancer Res. 2017;23:5737\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1434.","journal-title":"Clin Cancer Res"},{"key":"4402_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12920-024-01795-w","volume":"17","author":"FO Bagger","year":"2024","unstructured":"Bagger FO, Borgwardt L, Jespersen AS, Hansen AR, Bertelsen B, Kodama M, et al. Whole genome sequencing in clinical practice. BMC Med Genomics. 2024;17:39. https:\/\/doi.org\/10.1186\/s12920-024-01795-w.","journal-title":"BMC Med Genomics"},{"key":"4402_CR33","doi-asserted-by":"publisher","first-page":"12455","DOI":"10.1038\/s41598-025-94762-z","volume":"15","author":"M Ghosh","year":"2025","unstructured":"Ghosh M, Lingaraju SM, K CR, Balaram G, Kodandapani R, V E, et al. Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience. Sci Rep. 2025;15:12455. https:\/\/doi.org\/10.1038\/s41598-025-94762-z.","journal-title":"Sci Rep"},{"key":"4402_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2353\/jmoldx.2008.070178","volume":"10","author":"AR Li","year":"2008","unstructured":"Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, et al. EGFR mutations in lung adenocarcinomas. J Mol Diagn. 2008;10:242\u20138. https:\/\/doi.org\/10.2353\/jmoldx.2008.070178.","journal-title":"J Mol Diagn"},{"key":"4402_CR35","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","volume":"36","author":"JJ Lin","year":"2018","unstructured":"Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, et al. Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol. 2018;36:1199\u2013206. https:\/\/doi.org\/10.1200\/JCO.2017.76.2294.","journal-title":"J Clin Oncol"},{"key":"4402_CR36","doi-asserted-by":"publisher","first-page":"107293","DOI":"10.1016\/j.lungcan.2023.107293","volume":"184","author":"TKH Lim","year":"2023","unstructured":"Lim TKH, Skoulidis F, Kerr KM, Ahn M-J, Kapp JR, Soares FA, et al. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer. 2023;184:107293. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107293.","journal-title":"Lung Cancer"},{"key":"4402_CR37","doi-asserted-by":"publisher","first-page":"102080","DOI":"10.1016\/j.canep.2021.102080","volume":"76","author":"T John","year":"2022","unstructured":"John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn M-J. Uncommon EGFR mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol. 2022;76:102080. https:\/\/doi.org\/10.1016\/j.canep.2021.102080.","journal-title":"Cancer Epidemiol"},{"key":"4402_CR38","doi-asserted-by":"publisher","first-page":"100767","DOI":"10.1016\/j.ctarc.2023.100767","volume":"37","author":"F Proulx-Rocray","year":"2023","unstructured":"Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, et al. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Cancer Treat Res Commun. 2023;37:100767. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100767.","journal-title":"Cancer Treat Res Commun"},{"key":"4402_CR39","doi-asserted-by":"publisher","first-page":"1357583","DOI":"10.3389\/fonc.2024.1357583","volume":"14","author":"A Frille","year":"2024","unstructured":"Frille A, Boeschen M, Wirtz H, Stiller M, Bl\u00e4ker H, von Laffert M. TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations. Front Oncol. 2024;14:1357583. https:\/\/doi.org\/10.3389\/fonc.2024.1357583.","journal-title":"Front Oncol"},{"key":"4402_CR40","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892\u2013911.","journal-title":"Am J Cancer Res"},{"key":"4402_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5732\/cjc.011.10106","volume":"30","author":"W Zhou","year":"2011","unstructured":"Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011;30:287\u201392. https:\/\/doi.org\/10.5732\/cjc.011.10106.","journal-title":"Chin J Cancer"},{"key":"4402_CR42","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.21037\/tlcr-20-455","volume":"9","author":"HH-F Loong","year":"2020","unstructured":"Loong HH-F, Du N, Cheng C, Lin H, Guo J, Lin G, et al. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl Lung Cancer Res. 2020;9:1759\u201369. https:\/\/doi.org\/10.21037\/tlcr-20-455.","journal-title":"Transl Lung Cancer Res"},{"key":"4402_CR43","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1016\/j.cllc.2024.07.011","volume":"25","author":"P Jha","year":"2024","unstructured":"Jha P, Joshi A, Mishra R, Biswal RP, Kulkarni PM, Limaye S, et al. Landscape of clinically relevant genomic alterations in the Indian non-small cell lung cancer patients. Clin Lung Cancer. 2024;25:e420-e430.e20. https:\/\/doi.org\/10.1016\/j.cllc.2024.07.011.","journal-title":"Clin Lung Cancer"},{"key":"4402_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/alc.2024.131001","volume":"13","author":"A Jain","year":"2024","unstructured":"Jain A, Prabhash K, Radhakrishnan V, Srinivasan S. Epidemiology of EGFR mutation in adenocarcinoma NSCLC patients in India: a systematic review and meta-analysis. Adv Lung Cancer. 2024;13:1\u201321. https:\/\/doi.org\/10.4236\/alc.2024.131001.","journal-title":"Adv Lung Cancer"},{"key":"4402_CR45","doi-asserted-by":"publisher","first-page":"e76164","DOI":"10.1371\/journal.pone.0076164","volume":"8","author":"A Chougule","year":"2013","unstructured":"Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS ONE. 2013;8:e76164. https:\/\/doi.org\/10.1371\/journal.pone.0076164.","journal-title":"PLoS ONE"},{"key":"4402_CR46","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/j.cllc.2022.06.007","volume":"23","author":"R Hsu","year":"2022","unstructured":"Hsu R, Herrmann A, Gaur K, Xia B, Nieva JJ. Evaluating real world mutational differences between Hispanics and Asians in NSCLC at a large academic institution in Los Angeles. Clin Lung Cancer. 2022;23:e443\u201352. https:\/\/doi.org\/10.1016\/j.cllc.2022.06.007.","journal-title":"Clin Lung Cancer"},{"key":"4402_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241231260","author":"JC Laguna","year":"2024","unstructured":"Laguna JC, Garc\u00eda-Pardo M, Alessi J, Barrios C, Singh N, Al-Shamsi HO, et al. Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. Ther Adv Med Oncol. 2024. https:\/\/doi.org\/10.1177\/17588359241231260.","journal-title":"Ther Adv Med Oncol"},{"key":"4402_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/lungindia.lungindia_428_21","volume":"39","author":"M Roy","year":"2022","unstructured":"Roy M, Bal A, Gupta N, Prasad KT, Wakelee HA, Singh N. A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients. Lung India. 2022;39:315\u20138. https:\/\/doi.org\/10.4103\/lungindia.lungindia_428_21.","journal-title":"Lung India"},{"key":"4402_CR49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/ajco.13802","volume":"19","author":"R Raman","year":"2023","unstructured":"Raman R, Ramamohan V, Rathore A, Jain D, Mohan A, Vashistha V. Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Asia Pac J Clin Oncol. 2023;19:158\u201371. https:\/\/doi.org\/10.1111\/ajco.13802.","journal-title":"Asia Pac J Clin Oncol"},{"key":"4402_CR50","doi-asserted-by":"publisher","first-page":"155013","DOI":"10.1016\/j.prp.2023.155013","volume":"253","author":"A Aggarwal","year":"2024","unstructured":"Aggarwal A, Sharma S, Brar Z, Kumar V, Kumar A, Katara R, et al. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, an Indian perspective. Pathol Res Pract. 2024;253:155013. https:\/\/doi.org\/10.1016\/j.prp.2023.155013.","journal-title":"Pathol Res Pract"},{"key":"4402_CR51","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","volume":"24","author":"S Dearden","year":"2013","unstructured":"Dearden S, Stevens J, Wu Y-L, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdt205.","journal-title":"Ann Oncol"},{"key":"4402_CR52","doi-asserted-by":"publisher","first-page":"629","DOI":"10.21037\/tlcr-20-457","volume":"9","author":"W Gu","year":"2020","unstructured":"Gu W, Wang N, Gu W, Qiu Y, Zhang H, Liang J, et al. Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma. Transl Lung Cancer Res. 2020;9:629\u201338. https:\/\/doi.org\/10.21037\/tlcr-20-457.","journal-title":"Transl Lung Cancer Res"},{"key":"4402_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","volume":"8","author":"L Hong","year":"2024","unstructured":"Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, et al. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. NPJ Precis Oncol. 2024;8:217. https:\/\/doi.org\/10.1038\/s41698-024-00720-9.","journal-title":"NPJ Precis Oncol"},{"key":"4402_CR54","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.21037\/jtd.2019.08.61","volume":"12","author":"M Izumi","year":"2020","unstructured":"Izumi M, Suzumura T, Ogawa K, Matsumoto Y, Sawa K, Yoshimoto N, et al. Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian). J Thorac Dis. 2020;12:3776\u201384. https:\/\/doi.org\/10.21037\/jtd.2019.08.61.","journal-title":"J Thorac Dis"},{"key":"4402_CR55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/diagnostics16020245","volume":"16","author":"P-M Chen","year":"2026","unstructured":"Chen P-M, Huang Y-H, Li C-Y. Lung cancer in never-smokers: risk factors, driver mutations, and therapeutic advances. Diagnostics. 2026;16:245. https:\/\/doi.org\/10.3390\/diagnostics16020245.","journal-title":"Diagnostics"},{"key":"4402_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3157\/apjcb.2023.8.2.111-117","volume":"8","author":"RR Kishore","year":"2023","unstructured":"Kishore RR, Pan V. Correlation between ALK, ROS1 biomarkers and EGFR oncogene mutations in lung tumours: our observations in an apex oncopathology laboratory. Asian Pac J Cancer Biol. 2023;8:111\u20137. https:\/\/doi.org\/10.3157\/apjcb.2023.8.2.111-117.","journal-title":"Asian Pac J Cancer Biol"},{"key":"4402_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","volume":"6","author":"SG da Cunha","year":"2011","unstructured":"da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49\u201369. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130206.","journal-title":"Annu Rev Pathol"},{"key":"4402_CR58","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","journal-title":"N Engl J Med"},{"key":"4402_CR59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X.","journal-title":"Lancet Oncol"},{"key":"4402_CR60","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343:342\u201350. https:\/\/doi.org\/10.1124\/jpet.112.197756.","journal-title":"J Pharmacol Exp Ther"},{"key":"4402_CR61","first-page":"448","volume":"6","author":"SM Wirth","year":"2015","unstructured":"Wirth SM. Afatinib in non-small cell lung cancer. J Adv Pract Oncol. 2015;6:448\u201355.","journal-title":"J Adv Pract Oncol"},{"key":"4402_CR62","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390\u2013401. https:\/\/doi.org\/10.1016\/j.apsb.2015.07.001.","journal-title":"Acta Pharm Sin B"},{"key":"4402_CR63","doi-asserted-by":"publisher","first-page":"e000060","DOI":"10.1136\/esmoopen-2016-000060","volume":"1","author":"F Morgillo","year":"2016","unstructured":"Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1:e000060. https:\/\/doi.org\/10.1136\/esmoopen-2016-000060.","journal-title":"ESMO Open"},{"key":"4402_CR64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/2278-330X.110506","volume":"2","author":"K Prabhash","year":"2013","unstructured":"Prabhash K, Noronha V, Joshi A, Desai S, Sahu A. Crizotinib: a comprehensive review. South Asian J Cancer. 2013;2:91. https:\/\/doi.org\/10.4103\/2278-330X.110506.","journal-title":"South Asian J Cancer"},{"key":"4402_CR65","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"20","author":"AT Shaw","year":"2019","unstructured":"Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2019;20:1691\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(19)30655-2.","journal-title":"Lancet Oncol"},{"key":"4402_CR66","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41594-018-0061-5","volume":"25","author":"R Hansen","year":"2018","unstructured":"Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, et al. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. Nat Struct Mol Biol. 2018;25:454\u201362. https:\/\/doi.org\/10.1038\/s41594-018-0061-5.","journal-title":"Nat Struct Mol Biol"},{"key":"4402_CR67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation. New Eng J Med. 2022;387:120\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2204619.","journal-title":"New Eng J Med"},{"key":"4402_CR68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"key":"4402_CR69","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.1200\/JCO.2024.42.16_suppl.8606","volume":"42","author":"K-J Tang","year":"2024","unstructured":"Tang K-J, Liu B, Yao Y, Zhao Y, Zhou J, Sun P, et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion\u2013mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis. J Clin Oncol. 2024;42:8606\u20138606. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8606.","journal-title":"J Clin Oncol"},{"key":"4402_CR70","first-page":"94","volume":"9","author":"T Beardslee","year":"2018","unstructured":"Beardslee T, Lawson J. Alectinib and Brigatinib: new second-generation ALK inhibitors for the treatment of non-small cell lung cancer. J Adv Pract Oncol. 2018;9:94\u2013101.","journal-title":"J Adv Pract Oncol"},{"key":"4402_CR71","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, et al. Long-term outcomes and molecular correlates of Sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol. 2023;41:3311\u20137. https:\/\/doi.org\/10.1200\/JCO.22.02524.","journal-title":"J Clin Oncol"},{"key":"4402_CR72","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","volume":"406","author":"F Barlesi","year":"2025","unstructured":"Barlesi F, Yao W, Duruisseaux M, Doucet L, Mart\u00ednez AA, Gregorc V, et al. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet. 2025;406:615\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(25)00866-9.","journal-title":"Lancet"},{"key":"4402_CR73","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","volume":"23","author":"L Odogwu","year":"2018","unstructured":"Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg KB, Griffin N, et al. FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist. 2018;23:740\u20135. https:\/\/doi.org\/10.1634\/theoncologist.2017-0642.","journal-title":"Oncologist"},{"key":"4402_CR74","doi-asserted-by":"publisher","first-page":"9020","DOI":"10.1200\/JCO.2021.39.15_suppl.9020","volume":"39","author":"J Wolf","year":"2021","unstructured":"Wolf J, Garon EB, Groen HJM, Tan DS-W, Robeva A, Le Mouhaer S, et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study. J Clin Oncol. 2021;39:9020\u20139020. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9020.","journal-title":"J Clin Oncol"},{"key":"4402_CR75","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","volume":"9","author":"J Mazieres","year":"2023","unstructured":"Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, et al. Tepotinib treatment in patients with MET Exon 14\u2013skipping non-small cell lung cancer. JAMA Oncol. 2023;9:1260. https:\/\/doi.org\/10.1001\/jamaoncol.2023.1962.","journal-title":"JAMA Oncol"},{"key":"4402_CR76","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","volume":"10","author":"Q Huang","year":"2025","unstructured":"Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, et al. Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther. 2025;10:186. https:\/\/doi.org\/10.1038\/s41392-025-02243-6.","journal-title":"Signal Transduct Target Ther"},{"key":"4402_CR77","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1016\/j.csbj.2021.06.007","volume":"19","author":"RC Maloney","year":"2021","unstructured":"Maloney RC, Zhang M, Jang H, Nussinov R. The mechanism of activation of monomeric B-Raf V600E. Comput Struct Biotechnol J. 2021;19:3349\u201363. https:\/\/doi.org\/10.1016\/j.csbj.2021.06.007.","journal-title":"Comput Struct Biotechnol J"},{"key":"4402_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41698-024-00552-7","volume":"8","author":"D Planchard","year":"2024","unstructured":"Planchard D, Sanborn RE, Negrao MV, Vaishnavi A, Smit EF. BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape. npj Precis Oncol. 2024;8:90. https:\/\/doi.org\/10.1038\/s41698-024-00552-7.","journal-title":"npj Precis Oncol"},{"key":"4402_CR79","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","volume":"25","author":"J Wolf","year":"2024","unstructured":"Wolf J, Hochmair M, Han J-Y, Reguart N, Souquet P-J, Smit EF, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024;25:1357\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(24)00441-8.","journal-title":"Lancet Oncol"},{"key":"4402_CR80","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations. N Engl J Med. 2020;383:931\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2004407.","journal-title":"N Engl J Med"},{"key":"4402_CR81","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/1878-0261.70109","volume":"19","author":"F Zwierenga","year":"2025","unstructured":"Zwierenga F, Dijkhuizen C, Korthuis P, Timens W, Groen H, Hiltermann J, et al. The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients. Mol Oncol. 2025;19:3023\u201334. https:\/\/doi.org\/10.1002\/1878-0261.70109.","journal-title":"Mol Oncol"},{"key":"4402_CR82","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3747\/co.26.5137","volume":"26","author":"DG Bebb","year":"2019","unstructured":"Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, et al. Crizotinib inhibition of ROS1-Positive tumours in advanced non-small-cell lung cancer: a Canadian perspective. Curr Oncol. 2019;26:551\u20137. https:\/\/doi.org\/10.3747\/co.26.5137.","journal-title":"Curr Oncol"},{"key":"4402_CR83","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2022.12.018","volume":"170","author":"D Mauricio","year":"2023","unstructured":"Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella DD, Demirkiran C, et al. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody\u2013drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/neu expression. Gynecol Oncol. 2023;170:38\u201345. https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.018.","journal-title":"Gynecol Oncol"},{"key":"4402_CR84","doi-asserted-by":"publisher","first-page":"11517","DOI":"10.3390\/ijms262311517","volume":"26","author":"S Peshin","year":"2025","unstructured":"Peshin S, Takrori E, Yazji JH, Haque J, Dharia A, Mithani MS, et al. Advances in targeted therapy for non-small-cell lung cancer: current progress and future directions. Int J Mol Sci. 2025;26:11517. https:\/\/doi.org\/10.3390\/ijms262311517.","journal-title":"Int J Mol Sci"},{"key":"4402_CR85","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jjco\/hyad052","volume":"53","author":"T Araki","year":"2023","unstructured":"Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Jpn J Clin Oncol. 2023;53:547\u201361. https:\/\/doi.org\/10.1093\/jjco\/hyad052.","journal-title":"Jpn J Clin Oncol"},{"key":"4402_CR86","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fonc.2014.00244","volume":"4","author":"B Melosky","year":"2014","unstructured":"Melosky B. Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol. 2014;4:244. https:\/\/doi.org\/10.3389\/fonc.2014.00244.","journal-title":"Front Oncol"},{"key":"4402_CR87","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.3390\/jcm13216391","volume":"13","author":"C Sha","year":"2024","unstructured":"Sha C, Lee PC. EGFR-targeted therapies: a literature review. J Clin Med. 2024;13:6391. https:\/\/doi.org\/10.3390\/jcm13216391.","journal-title":"J Clin Med"},{"key":"4402_CR88","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/1759-7714.14858","volume":"14","author":"Y Meng","year":"2023","unstructured":"Meng Y, Bai R, Cui J. Precision targeted therapy for EGFR mutation\u2010positive NSCLC: dilemmas and coping strategies. Thorac Cancer. 2023;14:1121\u201334. https:\/\/doi.org\/10.1111\/1759-7714.14858.","journal-title":"Thorac Cancer"},{"key":"4402_CR89","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3892\/ol.2022.13528","volume":"24","author":"R Sun","year":"2022","unstructured":"Sun R, Hou Z, Zhang Y, Jiang B. Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma. Oncol Lett. 2022;24:408. https:\/\/doi.org\/10.3892\/ol.2022.13528.","journal-title":"Oncol Lett"},{"key":"4402_CR90","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","volume":"21","author":"D Ercan","year":"2015","unstructured":"Ercan D, Choi HG, Yun C-H, Capelletti M, Xie T, Eck MJ, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 2015;21:3913\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2789.","journal-title":"Clin Cancer Res"},{"key":"4402_CR91","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/JCO.23.02761","volume":"43","author":"IUS Leong","year":"2025","unstructured":"Leong IUS, Cabrera CP, Cipriani V, Ross PJ, Turner RM, Stuckey A, et al. Large-scale pharmacogenomics analysis of patients with cancer within the 100,000 Genomes Project combining whole-genome sequencing and medical records to inform clinical practice. J Clin Oncol. 2025;43:682\u201393. https:\/\/doi.org\/10.1200\/JCO.23.02761.","journal-title":"J Clin Oncol"},{"key":"4402_CR92","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/cancers17060913","volume":"17","author":"R S\u00e1nchez-Bayona","year":"2025","unstructured":"S\u00e1nchez-Bayona R, Catal\u00e1n C, Cobos MA, Bergamino M. Pharmacogenomics in solid tumors: a comprehensive review of genetic variability and its clinical implications. Cancers (Basel). 2025;17:913. https:\/\/doi.org\/10.3390\/cancers17060913.","journal-title":"Cancers (Basel)"},{"key":"4402_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.17305\/bjbms.2022.7953","volume":"23","author":"S Vranic","year":"2023","unstructured":"Vranic S, Gatalica Z. PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol Biomed. 2023;23:15\u201325. https:\/\/doi.org\/10.17305\/bjbms.2022.7953.","journal-title":"Biomol Biomed"},{"key":"4402_CR94","doi-asserted-by":"publisher","first-page":"101461","DOI":"10.1016\/j.rechem.2024.101461","volume":"7","author":"R Shaikh","year":"2024","unstructured":"Shaikh R, Bhattacharya S, Prajapati BG. Microsatellite instability: a potential game-changer in colorectal cancer diagnosis and treatment. Results Chem. 2024;7:101461. https:\/\/doi.org\/10.1016\/j.rechem.2024.101461.","journal-title":"Results Chem"},{"key":"4402_CR95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13000-018-0728-6","volume":"13","author":"C Li","year":"2018","unstructured":"Li C, Jia R, Liu H, Zhang B, Wang C. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Diagn Pathol. 2018;13:49. https:\/\/doi.org\/10.1186\/s13000-018-0728-6.","journal-title":"Diagn Pathol"},{"key":"4402_CR96","doi-asserted-by":"publisher","first-page":"550","DOI":"10.21037\/jtd.2019.12.122","volume":"12","author":"H Li","year":"2020","unstructured":"Li H, Wang J, Zhang G, Li Y, Lin L, Yang H, et al. Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world. J Thorac Dis. 2020;12:550\u20137. https:\/\/doi.org\/10.21037\/jtd.2019.12.122.","journal-title":"J Thorac Dis"},{"key":"4402_CR97","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1002\/cncr.34628","volume":"130","author":"AH Fox","year":"2024","unstructured":"Fox AH, Osarogiagbon RU, Farjah F, Jett JR, Johnson BE, Rivera MP, et al. The American Cancer Society National Lung Cancer Roundtable strategic plan: advancing comprehensive biomarker testing in non-small cell lung cancer. Cancer. 2024;130:4188\u201399. https:\/\/doi.org\/10.1002\/cncr.34628.","journal-title":"Cancer"},{"key":"4402_CR98","doi-asserted-by":"publisher","DOI":"10.33590\/emjoncol\/OEHS9513","author":"M Salhi","year":"2025","unstructured":"Salhi M. Integrated multi-omics approaches in non-small cell lung cancer for biomarker and pathway discovery. EMJ Oncol. 2025. https:\/\/doi.org\/10.33590\/emjoncol\/OEHS9513.","journal-title":"EMJ Oncol"},{"key":"4402_CR99","doi-asserted-by":"publisher","first-page":"e0317296","DOI":"10.1371\/journal.pone.0317296","volume":"20","author":"MS Rabby","year":"2025","unstructured":"Rabby MS, Islam MM, Kumar S, Maniruzzaman M, Hasan MAM, Tomioka Y, et al. Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches. PLoS ONE. 2025;20:e0317296. https:\/\/doi.org\/10.1371\/journal.pone.0317296.","journal-title":"PLoS ONE"},{"key":"4402_CR100","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/j.jtho.2021.07.032","volume":"16","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, et al. Programmed death-ligand 1 tumor proportion score and overall survival from first-line Pembrolizumab in patients with nonsquamous versus squamous NSCLC. J Thorac Oncol. 2021;16:2139\u201343. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.032.","journal-title":"J Thorac Oncol"},{"key":"4402_CR101","doi-asserted-by":"publisher","unstructured":"Ricciuti B, Elkrief A, Alessi JVM, Wang X, Barrichello AP de C, Pecci F, et al. Three-year outcomes and correlative analyses in patients with non-small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) \u2265 90% treated with first-line pembrolizumab. J Clin Oncol 2022;40:9043\u20139043. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9043.","DOI":"10.1200\/JCO.2022.40.16_suppl.9043"},{"key":"4402_CR102","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1007\/s12325-019-01057-7","volume":"36","author":"L Incorvaia","year":"2019","unstructured":"Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, et al. Programmed death ligand 1 (PD-L1) as a predictive biomarker for Pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC). Adv Ther. 2019;36:2600\u201317. https:\/\/doi.org\/10.1007\/s12325-019-01057-7.","journal-title":"Adv Ther"},{"key":"4402_CR103","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/annonc\/mdx008","volume":"28","author":"R Hui","year":"2017","unstructured":"Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a Phase 1 trial. Ann Oncol. 2017;28:874\u201381. https:\/\/doi.org\/10.1093\/annonc\/mdx008.","journal-title":"Ann Oncol"},{"key":"4402_CR104","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","volume":"25","author":"SJ Klempner","year":"2020","unstructured":"Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist. 2020;25:e147\u201359. https:\/\/doi.org\/10.1634\/theoncologist.2019-0244.","journal-title":"Oncologist"},{"key":"4402_CR105","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1002\/1878-0261.70054","volume":"19","author":"C Swanton","year":"2025","unstructured":"Swanton C, Madison RW, Tambaoan CFB, Meric-Bernstam F, Sweeney CJ, Kurzrock R, et al. Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab. Mol Oncol. 2025;19:3060\u201378. https:\/\/doi.org\/10.1002\/1878-0261.70054.","journal-title":"Mol Oncol"},{"key":"4402_CR106","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.3390\/cancers15235616","volume":"15","author":"J Nemunaitis","year":"2023","unstructured":"Nemunaitis J, Stanbery L, Willoughby D, Bognar E, Brun S, Walter A, et al. Clonal neoantigen: emerging \u201cmechanism-based\u201d biomarker of immunotherapy response. Cancers (Basel). 2023;15:5616. https:\/\/doi.org\/10.3390\/cancers15235616.","journal-title":"Cancers (Basel)"},{"key":"4402_CR107","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4103\/0366-6999.176084","volume":"129","author":"L Li","year":"2016","unstructured":"Li L, Dong M, Wang X-G. The implication and significance of beta 2 microglobulin. Chin Med J (Engl). 2016;129:448\u201355. https:\/\/doi.org\/10.4103\/0366-6999.176084.","journal-title":"Chin Med J (Engl)"},{"key":"4402_CR108","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.21037\/jtd-21-1377","volume":"14","author":"J Malhotra","year":"2022","unstructured":"Malhotra J, Ryan B, Patel M, Chan N, Guo Y, Aisner J, et al. Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer. J Thorac Dis. 2022;14:1772\u201383. https:\/\/doi.org\/10.21037\/jtd-21-1377.","journal-title":"J Thorac Dis"},{"key":"4402_CR109","doi-asserted-by":"publisher","first-page":"113295","DOI":"10.1016\/j.celrep.2023.113295","volume":"42","author":"A-M Zavitsanou","year":"2023","unstructured":"Zavitsanou A-M, Pillai R, Hao Y, Wu WL, Bartnicki E, Karakousi T, et al. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Rep. 2023;42:113295. https:\/\/doi.org\/10.1016\/j.celrep.2023.113295.","journal-title":"Cell Rep"},{"key":"4402_CR110","doi-asserted-by":"publisher","first-page":"12402","DOI":"10.3390\/ijms252212402","volume":"25","author":"M Roszkowska","year":"2024","unstructured":"Roszkowska M. Multilevel mechanisms of cancer drug resistance. Int J Mol Sci. 2024;25:12402. https:\/\/doi.org\/10.3390\/ijms252212402.","journal-title":"Int J Mol Sci"},{"key":"4402_CR111","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaoncol.2015.1066","volume":"1","author":"HA Yu","year":"2015","unstructured":"Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor. JAMA Oncol. 2015;1:982. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1066.","journal-title":"JAMA Oncol"},{"key":"4402_CR112","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1111\/cas.14593","volume":"111","author":"A Nishiyama","year":"2020","unstructured":"Nishiyama A, Takeuchi S, Adachi Y, Otani S, Tanimoto A, Sasaki M, et al. MET amplification results in heterogeneous responses to osimertinib in EGFR\u2010mutant lung cancer treated with erlotinib. Cancer Sci. 2020;111:3813\u201323. https:\/\/doi.org\/10.1111\/cas.14593.","journal-title":"Cancer Sci"},{"key":"4402_CR113","doi-asserted-by":"publisher","first-page":"21651","DOI":"10.1002\/cam4.6721","volume":"12","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xu J, Lan T, Zhou C, Liu P. The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity. Cancer Med. 2023;12:21651\u201365. https:\/\/doi.org\/10.1002\/cam4.6721.","journal-title":"Cancer Med"},{"key":"4402_CR114","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s12276-025-01493-2","volume":"57","author":"N Yu","year":"2025","unstructured":"Yu N, Hwang M, Ahn BC, Lee Y, Hong S, Sim H, et al. Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor\u2013tyrosine kinase inhibitor resistance subclones. Exp Mol Med. 2025;57:1567\u201378. https:\/\/doi.org\/10.1038\/s12276-025-01493-2.","journal-title":"Exp Mol Med"},{"key":"4402_CR115","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","volume":"8","author":"RA Burrell","year":"2014","unstructured":"Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8:1095\u2013111. https:\/\/doi.org\/10.1016\/j.molonc.2014.06.005.","journal-title":"Mol Oncol"},{"key":"4402_CR116","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/cancers15041314","volume":"15","author":"J Zheng","year":"2023","unstructured":"Zheng J, Zhou X, Fu Y, Chen Q. Advances in the study of hyperprogression of different tumors treated with PD-1\/PD-L1 antibody and the mechanisms of its occurrence. Cancers (Basel). 2023;15:1314. https:\/\/doi.org\/10.3390\/cancers15041314.","journal-title":"Cancers (Basel)"},{"key":"4402_CR117","doi-asserted-by":"publisher","first-page":"100396","DOI":"10.1016\/j.jtocrr.2022.100396","volume":"3","author":"M Wilgucki","year":"2022","unstructured":"Wilgucki M, Yeung V, Ho G, Bravo Montenegro GL, Jones G, Reuss JE, et al. Osimertinib and Capmatinib combination therapy to overcome MET Y1003N-mediated resistance in EGFR-mutant NSCLC: a case report. JTO Clin Res Rep. 2022;3:100396. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100396.","journal-title":"JTO Clin Res Rep"},{"key":"4402_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1488345","author":"X Qi","year":"2024","unstructured":"Qi X, Cheng C, Zhang D, Yu Z, Meng X. Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1488345.","journal-title":"Front Immunol"},{"key":"4402_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.758464","author":"Y Choudhury","year":"2022","unstructured":"Choudhury Y, Tan M-H, Shi JL, Tee A, Ngeow KC, Poh J, et al. Complementing tissue testing with plasma mutation profiling improves therapeutic decision-making for patients with lung cancer. Front Med. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.758464.","journal-title":"Front Med"},{"key":"4402_CR120","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Ther. 2024;9:336. https:\/\/doi.org\/10.1038\/s41392-024-02021-w.","journal-title":"Signal Transduct Target Ther"},{"key":"4402_CR121","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025;9:84. https:\/\/doi.org\/10.1038\/s41698-025-00876-y.","journal-title":"NPJ Precis Oncol"},{"key":"4402_CR122","doi-asserted-by":"publisher","first-page":"185","DOI":"10.36401\/JIPO-23-22","volume":"6","author":"AF Cardona","year":"2023","unstructured":"Cardona AF, \u00c1vila V, Arrieta O. Treatment for advanced non-small lung cancer (NSCLC) with mutated EGFR in low- and middle-income countries (LMICs). J Immunother Precis Oncol. 2023;6:185\u20136. https:\/\/doi.org\/10.36401\/JIPO-23-22.","journal-title":"J Immunother Precis Oncol"},{"key":"4402_CR123","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.21037\/jtd-22-312","volume":"14","author":"K Lu","year":"2022","unstructured":"Lu K, Husain H. Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations. J Thorac Dis. 2022;14:1299\u2013301. https:\/\/doi.org\/10.21037\/jtd-22-312.","journal-title":"J Thorac Dis"},{"key":"4402_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1648987","author":"Q Gao","year":"2025","unstructured":"Gao Q, Wu H, Duan L, Lv G, Quan D. Multi-omics analysis of the tumor microenvironment after metastasis: advancing toward personalized immunotherapy and molecular targeted strategies. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1648987.","journal-title":"Front Immunol"},{"key":"4402_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554871","author":"J Zhang","year":"2025","unstructured":"Zhang J, Song Z, Zhang Y, Zhang C, Xue Q, Zhang G, et al. Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1554871.","journal-title":"Front Immunol"},{"key":"4402_CR126","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3390\/bios15110737","volume":"15","author":"M-R Ki","year":"2025","unstructured":"Ki M-R, Kim DH, Abdelhamid MAA, Pack SP. Cancer and aging biomarkers: classification, early detection technologies and emerging research trends. Biosensors (Basel). 2025;15:737. https:\/\/doi.org\/10.3390\/bios15110737.","journal-title":"Biosensors (Basel)"},{"key":"4402_CR127","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/genes16101168","volume":"16","author":"MA Boti","year":"2025","unstructured":"Boti MA, Diamantopoulos MA, Scorilas A. RNA-targeting techniques: a comparative analysis of modern approaches for RNA manipulation in cancer research and therapeutics. Genes. 2025;16:1168. https:\/\/doi.org\/10.3390\/genes16101168.","journal-title":"Genes"},{"key":"4402_CR128","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3390\/jcm14103574","volume":"14","author":"D Giansanti","year":"2025","unstructured":"Giansanti D, Morelli S. Exploring the potential of digital twins in cancer treatment: a narrative review of reviews. J Clin Med. 2025;14:3574. https:\/\/doi.org\/10.3390\/jcm14103574.","journal-title":"J Clin Med"},{"key":"4402_CR129","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/PGPM.S62918","volume":"9","author":"J Patel","year":"2016","unstructured":"Patel J. Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmgenom Pers Med. 2016;9:65\u201377. https:\/\/doi.org\/10.2147\/PGPM.S62918.","journal-title":"Pharmgenom Pers Med"},{"key":"4402_CR130","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.2147\/JMDH.S458564","volume":"17","author":"Y Ausi","year":"2024","unstructured":"Ausi Y, Barliana M, Postma M, Suwantika A. One step ahead in realizing pharmacogenetics in low- and middle-income countries: what should we do? J Multidiscip Healthc. 2024;17:4863\u201374. https:\/\/doi.org\/10.2147\/JMDH.S458564.","journal-title":"J Multidiscip Healthc"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04402-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:28:25Z","timestamp":1783942105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04402-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":130,"alternative-id":["4402"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04402-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent was not required for this study because it is based exclusively on previously published literature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}